China Resources Medical Issues 2025 Profit Warning: Key Details for Investors

Summary of Announcement

China Resources Medical Holdings Company Limited has issued a profit warning for the fiscal year ended December 31, 2025. The Board of Directors has cautioned shareholders and potential investors that the company expects a significant decline in profit attributable to owners compared to the previous year.

Key Financial Highlights

• Estimated 2025 Profit: The profit attributable to owners for the year is projected to range between RMB467 million and RMB516 million, a decrease of approximately 17.5% to 8.9% from RMB566 million in 2024.
• Impact of One-Off Compensation: The company received a one-off compensation of approximately RMB210 million for management fees and supply chain loss under the Yan Hua IOT Agreement in 2025. After excluding this compensation and the related income tax, the adjusted profit would show a much steeper decline of 43.5% to 37.6% compared to 2024.
• First Half Comparison: The decrease in profit (excluding the Yan Hua Compensation) for the full year 2025, though significant, is less severe than the 57.4% decline reported for the first half of 2025 versus the same period in 2024, indicating a narrowing of the profit drop in the second half.

Factors Impacting Profitability

• Decrease in Operating Profits: The primary driver of the profit decline is a reduction in operating profits at member medical institutions, largely due to a decrease in average medical insurance fee per visit.
• IOT Business Scaling Back: The company has scaled back its “invest-operate-transfer” (IOT) business model, contributing further to the profit decline.

Company Response and Strategic Initiatives

• Revenue Structure Optimization: Since the second half of 2025, China Resources Medical has been proactively working on optimizing its revenue structure, refining management, and controlling operating costs to improve operational performance.
• Positive Second Half Trends: Both revenue and patient visit numbers increased in the second half of 2025 compared to the first half, suggesting some recovery in business activity.
• Debt Reduction: Bank borrowings were reduced by approximately RMB780 million from end-2024 levels, leading to a lower interest-bearing debt ratio and maintaining sufficient cash flow.
• Healthcare Management Revenue: Revenue from healthcare management increased in 2025 compared to 2024, reflecting growth in this segment.
• Expansion into Full-Cycle Health Services: The company expanded into full-cycle health services, setting up a “Runxin healthcare hut” at China Resources Tower in Shenzhen to provide on-site services for enterprises.
• Innovation in Services: New initiatives include “doctors in the neighborhood” and “internet+in-home nursing” in certain regions, extending household healthcare services and laying the groundwork for a full-cycle intelligent health services model.

Important Notes for Shareholders

• Results Not Yet Finalized: The figures are based on unaudited management accounts and have not been reviewed by the audit committee or audited by external auditors. Final annual results will be released by the end of March 2026.
• Potential Share Price Impact: The significant drop in profit—especially after excluding one-off compensation—and the ongoing strategic changes are likely to be price sensitive and may affect the share value.
• Caution Advised: Shareholders and potential investors are urged to exercise caution in trading the company’s shares until the audited results are published.

Board Composition

As of the date of the announcement, the Board consists of Mr. YU Hai (Chairman), Mr. ZHANG Chuang, Mr. WANG Yuexing, and Mr. WU Xinchun as executive Directors; Ms. GE Lu as non-executive Director; and Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng, and Ms. LO Wing Sze as independent non-executive Directors.

Conclusion

The profit warning issued by China Resources Medical Holdings is a material development and likely to influence the company’s share price. The combination of a sharp decline in profits, changes in business mix, and ongoing strategic transformation signals a challenging period, but also reflects the company’s efforts to adapt to a changing market and regulatory environment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should refer to the company’s official filings and consult their financial advisors before making any investment decisions. The information is based on preliminary figures which are subject to change upon audit.

View CR MEDICAL Historical chart here